

Andreas Viardot

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2199961/publications.pdf>

Version: 2024-02-01

24
papers

5,845
citations

567281

15
h-index

580821

25
g-index

26
all docs

26
docs citations

26
times ranked

5848
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 1 | Tumor Regression in Cancer Patients by Very Low Doses of a T Cell-Engaging Antibody. <i>Science</i> , 2008, 321, 974-977. | 12.6 | 957 |
| 2 | PI3K Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma. <i>New England Journal of Medicine</i> , 2014, 370, 1008-1018. | 27.0 | 956 |
| 3 | Targeted Therapy With the T-Cell-Engaging Antibody Blinatumomab of Chemotherapy-Refractory Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Patients Results in High Response Rate and Prolonged Leukemia-Free Survival. <i>Journal of Clinical Oncology</i> , 2011, 29, 2493-2498. | 1.6 | 819 |
| 4 | Phase II Trial of the Anti-CD19 Bispecific T Cell-Engager Blinatumomab Shows Hematologic and Molecular Remissions in Patients With Relapsed or Refractory B-Precursor Acute Lymphoblastic Leukemia. <i>Journal of Clinical Oncology</i> , 2014, 32, 4134-4140. | 1.6 | 577 |
| 5 | Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL. <i>Blood</i> , 2012, 120, 5185-5187. | 1.4 | 435 |
| 6 | Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab. <i>Blood</i> , 2012, 119, 6226-6233. | 1.4 | 410 |
| 7 | Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation. <i>Blood</i> , 2012, 120, 2032-2041. | 1.4 | 381 |
| 8 | Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study. <i>Journal of Clinical Oncology</i> , 2016, 34, 1104-1111. | 1.6 | 359 |
| 9 | Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma. <i>Blood</i> , 2016, 127, 1410-1416. | 1.4 | 295 |
| 10 | High single-drug activity of nelarabine in relapsed T-lymphoblastic leukemia/lymphoma offers curative option with subsequent stem cell transplantation. <i>Blood</i> , 2011, 118, 3504-3511. | 1.4 | 158 |
| 11 | Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial. <i>Lancet</i> , 2019, 394, 2271-2281. | 13.7 | 155 |
| 12 | Long-term survival and T-cell kinetics in relapsed/refractory ALL patients who achieved MRD response after blinatumomab treatment. <i>Blood</i> , 2015, 126, 2578-2584. | 1.4 | 136 |
| 13 | Bispecific antibodies in haematological malignancies. <i>Cancer Treatment Reviews</i> , 2018, 65, 87-95. | 7.7 | 55 |
| 14 | A randomized phase 3 trial of auto vs. allo transplantation as part of first-line therapy in poor-risk peripheral T-NHL. <i>Blood</i> , 2021, 137, 2646-2656. | 1.4 | 39 |
| 15 | Concepts in immuno-oncology: tackling B cell malignancies with CD19-directed bispecific T cell engager therapies. <i>Annals of Hematology</i> , 2020, 99, 2215-2229. | 1.8 | 29 |
| 16 | Chimeric antigen receptor (CAR) T-cell therapy as a treatment option for patients with B-cell lymphomas: perspectives on the therapeutic potential of Axicabtagene ciloleucel. <i>Cancer Management and Research</i> , 2019, Volume 11, 2393-2404. | 1.9 | 14 |
| 17 | Durability of complete response after blinatumomab therapy for relapsed/refractory diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2020, 61, 2767-2770. | 1.3 | 14 |
| 18 | Outcomes of patients with up to 6 years of follow-up from a phase 2 study of idelalisib for relapsed indolent lymphomas. <i>Leukemia and Lymphoma</i> , 2021, 62, 1077-1087. | 1.3 | 13 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | First Results of the Risk-Adapted, MRD-Stratified GMALL Trial 08/2013 in 705 Adults with Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma (ALL/LBL). <i>Blood</i> , 2021, 138, 362-362. | 1.4 | 12 |
| 20 | Open-label, phase 2 study of blinatumomab after frontline R-chemotherapy in adults with newly diagnosed, high-risk DLBCL. <i>Leukemia and Lymphoma</i> , 2022, 63, 2063-2073. | 1.3 | 9 |
| 21 | Investigational immunotherapy targeting CD19 for the treatment of acute lymphoblastic leukemia. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 773-784. | 4.1 | 8 |
| 22 | Chemotherapy-Free Combination of Obinutuzumab and Ibrutinib in First LINE Treatment of Follicular Lymphoma. the Alternative Study By the German Low Grade Lymphoma Study Group (GLSG). <i>Blood</i> , 2018, 132, 448-448. | 1.4 | 6 |
| 23 | Significant reduced loss of bone mineral density after four vs. six cycles of R-CHOP: an analysis of the FLYER-trial. <i>Leukemia and Lymphoma</i> , 2022, 63, 326-334. | 1.3 | 3 |
| 24 | Pharmacotherapeutic management of T-cell acute lymphoblastic leukemia in adults: an update of the literature. <i>Expert Opinion on Pharmacotherapy</i> , 2022, 23, 561-571. | 1.8 | 3 |